WHO links tuberculosis outcomes with social and financial protection monitoring in a new framework. #HTA #HealthEconomics https://www.mattheneus.com/editorial/who-tuberculosis-social-protection-monitoring-financial-protection-framework-2026-10-08

Three modelling choices define the strongest consensus for CAR-T value cases. https://www.mattheneus.com/editorial/pubmed-car-t-economic-evaluation-nine-nice-appraisals-consensus-2026-10-09 #HTA #HealthEconomics #Pharma

A German consultation on pulmonary embolism thrombectomy puts population fit under the spotlight. https://www.mattheneus.com/editorial/g-ba-in-toto-thrombectomy-pulmonary-embolism-consultation-population-fit-2026-10-08 #HTA #EvidenceSynthesis #RegulatoryAffairs

WHO guidance puts mixed-methods evidence at the centre of community mental health transitions. https://www.mattheneus.com/editorial/who-community-mental-health-deinstitutionalization-guide-mixed-methods-2026-10-09 #HTA #RWE #HealthEconomics

Crohn's disease location can reshape comparative treatment efficacy and the network meta-analysis question. https://www.mattheneus.com/editorial/pubmed-crohns-disease-location-treatment-efficacy-nma-2026-10-08 #HTA #NMA #EvidenceSynthesis

A Cochrane review examines how pharmaceutical promotion shapes prescribing appropriateness, volume and cost. https://www.mattheneus.com/editorial/cochrane-pharmaceutical-promotion-prescribing-appropriateness-cost-review-2026-10-09 #HTA #Pharma #HealthEconomics

WHO maps 19 guidelines and 20 research priorities for hypertensive pregnancy care. https://www.mattheneus.com/editorial/who-hypertensive-pregnancy-roadmap-guideline-convergence-research-priorities-2026-10-08 #HTA #RegulatoryAffairs

Poland’s conditional Tevimbra recommendation shows how comparator updates shape reimbursement. https://www.mattheneus.com/editorial/aotmit-tevimbra-tislelizumab-conditional-reimbursement-risk-sharing-2026-10-07 #HTA #Pharma #RegulatoryAffairs

Six asthma studies show what a strong local value case for combination reliever access needs. https://www.mattheneus.com/editorial/asthma-ics-formoterol-cost-effectiveness-local-value-file-2026-10-08 #HTA #HealthEconomics #RWE

French reassessment highlights how outcomes evidence can reshape reimbursement decisions. https://www.mattheneus.com/editorial/has-zimino-levosimendan-reassessment-insufficient-clinical-benefit-2026-08-26 #HTA #EvidenceSynthesis #Pharma

France's early access refusal for Pyrukynd highlights how evidence and access criteria shape rare-disease decisions. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/has-pyrukynd-mitapivat-sickle-cell-early-access-refusal-riseup-2026-10-01

How do perioperative chemotherapy cycle strategies compare in gastric cancer? A new network meta-analysis maps the evidence. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/world-journal-gastric-cancer-perioperative-cycle-network-meta-analysis-2026-10-08

Seven new studies left this living treatment network's conclusions unchanged. See what quarterly surveillance reveals. https://www.mattheneus.com/editorial/pubmed-living-nma-quarterly-surveillance-stable-conclusions-2026-10-08 #HTA #NMA #EvidenceSynthesis

A zero-event study can leave exploratory dressing comparisons unresolved. See how unanchored MAIC frames the residual uncertainty.

https://www.mattheneus.com/editorial/sacral-dressing-unanchored-maic-residual-differences-2026-10-07

#HTA #MAIC #EvidenceSynthesis #HealthEconomics

Germany’s G-BA leaves Zynyz’s benefit magnitude open after a single-arm Merkel cell carcinoma study. https://www.mattheneus.com/editorial/g-ba-zynyz-mcc-benefit-extent-single-arm-podium201-2026-10-01 #HTA #HealthEconomics #RegulatoryAffairs

A 55-study review maps treatment de-escalation across 13 atopic dermatitis regimens. https://www.mattheneus.com/editorial/pubmed-atopic-dermatitis-treatment-deescalation-network-meta-analysis-2026-10-03 #HTA #NMA #EvidenceSynthesis

Portugal’s EU JCA alignment map shows that outcome scoping carries the largest methodology gap. https://www.mattheneus.com/editorial/portugal-eu-jca-methodology-alignment-outcome-scoping-gaps-2026-10-07 #HTA #EvidenceSynthesis #RegulatoryAffairs

EU selects its first two medical devices for joint clinical assessment. https://www.mattheneus.com/editorial/european-commission-first-medical-device-jca-sapien-m3-highlife-mitral-valves-2026-10-06 #HTA #RegulatoryAffairs #HealthEconomics

WHO updates pre-eclampsia evidence across magnesium sulfate, aspirin and calcium, sharpening priorities for maternal health. https://www.mattheneus.com/editorial/who-pre-eclampsia-fact-sheet-magnesium-aspirin-calcium-evidence-2026-10-06 #HTA #EvidenceSynthesis #HealthEconomics

Arm-wise target matching is now available for anchored MAIC in AbangeLabs HTA Studio. https://www.mattheneus.com/editorial/abangelabs-hta-studio-anchored-maic-weighting-strategy-arm-wise-target-matching-2026-10-08 #HTA #MAIC #EvidenceSynthesis